Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
In first-line NSCLC the drug beats chemo, and not Keytruda.
And the company might one day follow Galapagos into decentralised manufacturing.
The group claims a seven-day vein-to-vein time is unique, and says why this matters.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The company’s TARA-002 produces competitive results in BCG-unresponsive bladder cancer, albeit in just five patients.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
